INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10541687	
Filing Date		2005-11-21	
First Named Inventor	DEADWYLER		
Art Unit		1615	
Examiner Name	KIM, Jennifer M.		
Attorney Docket Number		C21-074US Nat	

		Attention Decide Hamisti				
	1	INGVAR M et al., Enhancement by an ampakine of memory encoding in humans. Exp. Neurol. 1997 Aug; 146 (2):553-9. Abstract only.				
	2	OFF DC et al., The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. sychiatry 2001 Sep; 158(9):1357-77. Abstract only.				
	3 ⁻	MARCENO S et al., Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr Res. 2002 Oct 1; 57(2-3):221-6. Abstract only.				
	4	MACKOWIAK M et al., An AMPA receptor potentiator modulates hippocampal expression of BDMF: an in vivo study. Neuropharmacology 2002; 43:1-10.				
	5	QUIRK JC et al., LY404187: A Novel Positive Allosteric Modulator of AMPA Receptors. CNS Drug Reviews 2002; 8 (3):255-282.				
If you wish to add additional non-patent literature document citation information please click the Add button						
EXAMINER SIGNATURE						
Examiner Signature		re Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						
¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.						